SARS-CoV-2 T cell immunity: Specificity, function, durability, and role in protection
- PMID: 32680954
- DOI: 10.1126/sciimmunol.abd6160
SARS-CoV-2 T cell immunity: Specificity, function, durability, and role in protection
Abstract
In efforts to synthesize a clear understanding of SARS-CoV-2 protective immunity, antibody analysis has been paralleled by T cell studies across asymptomatic, mild and severe COVID-19. Defining CD4 and CD8 effector functions in protection is important considering that antibody responses appear short-lived and T cell memory is potentially more durable. To fully understand population level immunity, screening for both antibody and T cell immunity using standardized testing methods would be beneficial.
Copyright © 2020, American Association for the Advancement of Science.
Similar articles
-
An Effective COVID-19 Vaccine Needs to Engage T Cells.Front Immunol. 2020 Sep 28;11:581807. doi: 10.3389/fimmu.2020.581807. eCollection 2020. Front Immunol. 2020. PMID: 33117391 Free PMC article. No abstract available.
-
Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19.Nat Immunol. 2020 Nov;21(11):1336-1345. doi: 10.1038/s41590-020-0782-6. Epub 2020 Sep 4. Nat Immunol. 2020. PMID: 32887977 Free PMC article.
-
Acute SARS-CoV-2 Infection Impairs Dendritic Cell and T Cell Responses.Immunity. 2020 Oct 13;53(4):864-877.e5. doi: 10.1016/j.immuni.2020.07.026. Epub 2020 Aug 4. Immunity. 2020. PMID: 32791036 Free PMC article.
-
The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic.Mult Scler Relat Disord. 2020 Aug;43:102174. doi: 10.1016/j.msard.2020.102174. Epub 2020 May 12. Mult Scler Relat Disord. 2020. PMID: 32464584 Free PMC article. Review.
-
MAIT Cells in COVID-19: Heroes, Villains, or Both?Crit Rev Immunol. 2020;40(2):173-184. doi: 10.1615/CritRevImmunol.2020034943. Crit Rev Immunol. 2020. PMID: 32749095 Review.
Cited by
-
Infection and Immune Memory: Variables in Robust Protection by Vaccines Against SARS-CoV-2.Front Immunol. 2021 May 11;12:660019. doi: 10.3389/fimmu.2021.660019. eCollection 2021. Front Immunol. 2021. PMID: 34046033 Free PMC article. Review.
-
Single-centre, randomised clinical trial of the immunomodulatory mechanisms of daily supplementation of palm tocotrienol-rich fraction in healthy human volunteers following influenza vaccination.F1000Res. 2024 Feb 22;13:135. doi: 10.12688/f1000research.137005.1. eCollection 2024. F1000Res. 2024. PMID: 39268057 Free PMC article. Clinical Trial.
-
Effectiveness of COVID-19 Vaccines against SARS-CoV-2 Omicron Variant (B.1.1.529): A Systematic Review with Meta-Analysis and Meta-Regression.Vaccines (Basel). 2022 Dec 19;10(12):2180. doi: 10.3390/vaccines10122180. Vaccines (Basel). 2022. PMID: 36560590 Free PMC article. Review.
-
A next-generation vaccine for broader and long-lasting COVID-19 protection.MedComm (2020). 2022 May 2;3(2):e138. doi: 10.1002/mco2.138. eCollection 2022 Jun. MedComm (2020). 2022. PMID: 35509871 Free PMC article. No abstract available.
-
Prevalence of COVID-19-associated symptoms during acute infection in relation to SARS-CoV-2-directed humoral and cellular immune responses in a mild-diseased convalescent cohort.Int J Infect Dis. 2022 Jul;120:187-195. doi: 10.1016/j.ijid.2022.04.019. Epub 2022 Apr 14. Int J Infect Dis. 2022. PMID: 35429640 Free PMC article.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous
